#USA #Anaheim #Ozelle #O-Cyte 1 #AI Hematology

Ozelle to Introduce O-Cyte 1 at ADLM 2026

In an exciting development for the field of hematology, Ozelle is set to unveil its latest innovation, the O-Cyte 1, at the upcoming ADLM 2026 conference in California. This event, known for showcasing cutting-edge advancements in laboratory diagnostics, will provide a platform for the world debut of this automated hematology analyzer. The O-Cyte 1 represents a significant leap forward in the integration of artificial intelligence (AI) within hematological testing, specifically in the realm of blood morphology analysis.

Cellular morphology has long been a critical aspect of hematological investigations, providing invaluable insights into blood disorders. However, the challenge has been effectively incorporating detailed morphological assessments into routine diagnostic workflows without compromising productivity. Traditional manual microscopy relies heavily on the expertise of highly trained specialists. On the other hand, image-based solutions have expanded laboratory capabilities but often struggle with seamless integration into high-throughput environments.

The O-Cyte 1 addresses these challenges by combining advanced morphologic analysis capabilities, a scalable throughput, and ease of use into a single, compact system. Powered by Ozelle’s proprietary AI times Complete Blood Morphology (AI × CBM) technology, this analyzer transforms cellular images into structured morphological information. This enhancement enables laboratories to transcend mere numerical readings and utilize image-based evidence for more consistent interpretations.

Designed to optimize clinical workflows, the O-Cyte 1 can conduct up to 60 tests per hour in autonomous mode and escalate to 360 tests per hour with a cascade extension. Its compact footprint, modular architecture, minimal maintenance requirements, and maintenance-friendly design are intended to empower healthcare professionals and laboratory managers to enhance efficiency while reducing operational complexity.

Raymond, the director of Ozelle North America division, expressed enthusiasm about this launch, stating, "O-Cyte 1 embodies our vision to make advanced morphological analysis more practical, scalable, and accessible for everyday hematological processes. At ADLM 2026, we are eager to demonstrate to our international partners how AI-based morphology can integrate into more productive workflows in hematology."

During the ADLM 2026 event, Ozelle will showcase the O-Cyte 1 alongside its comprehensive range of products tailored for clinical hematology. With rising demand for effective and scalable hematological solutions across North America, Europe, the Middle East, Southeast Asia, India, and beyond, Ozelle aims to support various clinical environments through AI-based diagnostic systems designed for daily practice.

Visitors and partners are encouraged to explore the O-Cyte 1 at Booth 2517 during ADLM 2026, which runs from July 28 to July 30 at the Anaheim Convention Center. Partners unable to attend the event in person are invited to reach out via email for product demonstrations and collaboration opportunities in their respective regions.

For more information, please visit Ozelle's website at www.ozellemed.com or contact them via email at [email protected]